Biopharma companies put the brakes on product deals last year, with the drop driven by a decline in oncology transactions. Meanwhile, a look at the big spenders shows how…
One day after Biogen expands aducanumab trials, a canary in the coal mine, the rival crenezumab, fails in phase III.
A collaboration over four gene therapy programmes substantially beefs up Neurocrine’s pipeline, while Voyager Therapeutics gets a much-needed infusion of credibility.
The heavily promoted company’s cell therapy fails a key study in ischaemic stroke.
A dissection of five years' biopharma buyout spending reveals that most deals are struck over preclinical and mid-stage assets, while buyers remain most interested…
Allergan needs a win with rapastinel, while Lundbeck's chief exec faces her second clinical challenge.
Fresh from a mid-stage success in depression Axsome offers an unusual way to trade its upcoming phase III result.
Jazz wants to expand its sleep portfolio, while Macrogenics hopes trial data will support its first new drug application.
Alnylam appears to have turned its Onpattro launch around, but is adamant that investors should have been more patient all along.